Category: Uncategorized

CONFLUENCE. Imagine for a moment. Agile and fast-moving Robots, controlled by thought, that give real-time bionic feedback of the senses; this goes beyond military uses, to search and rescue, terrestrial and extraterrestrial exploration, and distant work assignments. Sensate machines under human thought control working far away in hostile conditions. View in LinkedIn

PROSTHETICS WITH SENSE OF TOUCH. " " http://lnkd.in/biR7Wgy View in LinkedIn

MILITARY ROBOTS. "WildCat can bound, gallop and turn, mimicking the movements of quadruped animals. It is powered by an internal combustion engine."We do not know what military purpose it will serve but certainly it is a step towards a high-speed ground robot that could be weaponised to hunt and kill."" " http://lnkd.in/bK_47g8 View in LinkedIn

RESURGENCE OF OLD BIOMEDICINE. "In the United States, medicinal leeches (Hirudo medicinalis) were cleared as a medical device in June 2004 by the FDA (shortly after maggots received clearance) and are used today throughout the world as tools in skin grafts and reattachment microsurgery."" " http://lnkd.in/b8kRc48 View in LinkedIn

MAGGOT DEBRIDEMENT THERAPY. "Today, any physician in the U.S. can prescribe maggot therapy. There are over 800 health care centers in the United States that have utilized maggot therapy. Over 4,000 therapists are using maggot therapy in 20 countries. Approximately 50,000 treatments were applied to wounds in the year 2006. These data appear on the website of the Wound Care Information Network, but the original sources are not provided."" " http://lnkd.in/bZrfFXw View in LinkedIn

BIOTHERAPY. "Maggots received marketing clearance as "medical devices" by the FDA in January 2004, making them the first live organism marketed in the United States. Therapy is currently reimbursable by Medicare. About 50 centers in North America, 400 in the United Kingdom, more than 140 in Germany, and more worldwide currently offer maggot therapy as an option for treatment in wound care."" " http://lnkd.in/b8kRc48 View in LinkedIn

BIOTHERAPY. "Maggots received marketing clearance as "medical devices" by the FDA in January 2004, making them the first live organism marketed in the United States. Therapy is currently reimbursable by Medicare. About 50 centers in North America, 400 in the United Kingdom, more than 140 in Germany, and more worldwide currently offer maggot therapy as an option for treatment in wound care."" " http://lnkd.in/b8kRc48 View in LinkedIn

BUG ON BUG: "Studies show colonization with a non-disease-causing strain of C. difficile can prevent infection by the more dangerous strains. Patients who are not colonized by benign strains may risk become infected by the harmful strains. The harmless strains occupy the same niches in the intestine that the infective strains would take if the harmless strains weren't there."" " http://www.eurekalert.org/pub_releases/2013-10/asfm-bvb100213.php View in LinkedIn

BUGS TRAINED TO FIGHT BUGS. "They reprogrammed E. coli to sense Pseudomonas aeruginosa — a bacteria that can form biofilms and causes hospital-acquired infections. The new E. coli swims directly toward P. aeruginosa and launches an attack with an antimicrobial peptide and an enzyme that breaks down biofilms. Though the researchers successfully tested their engineered microbe on P. aeruginosa, they say that their engineering strategy could be used to combat other pathogens as well."" " http://www.eurekalert.org/pub_releases/2013-10/acs-rec100213.php View in LinkedIn

BIOFUELS. "Glycolysis is currently used in biorefinies to convert sugars derived from plant biomass into biofuels, but the loss of two carbon atoms for every six that are input is seen as a major gap in the efficiency of the process. A new synthetic glycolytic pathway converts all six glucose carbon atoms into three molecules of acetyl-CoA without losing any as carbon dioxide, (solving) one of the most significant limitations in biofuel production and biorefining: losing one-third of carbon from carbohydrate raw materials."" " http://www.eurekalert.org/pub_releases/2013-09/uoc--ued093013.php View in LinkedIn